Why is obesity defined as a disease - and when does it really endanger us?/Walla system
Weight loss injections are perhaps the hottest topic of the year in the health world, due to their ability to cause massive weight loss, but now the Wegovy weight loss drug is no longer only for diabetics or weight loss.
The U.S. Food and Drug Administration (FDA) recently approved drugmaker Novo Nordisk's request to add cardiovascular benefits to the drug's label, making it the first weight-loss drug also approved to reduce the risk of heart attack, stroke or heart-related death in people who are at higher risk for the conditions. these
Also effective for people at risk of heart disease.
Wegobi/Courtesy of The Pharmaceutical Company
"The evidence is that they reduce risk and save lives - so there is no defense in denying people access, or making it difficult for people to access, drugs that will directly improve their health," said Dr. Harlan Krumholtz, a cardiologist and scientist at Yale University and Yale New Haven Hospital, who is not In no way related to the manufacturing company, according to the CNN website.
"The point is that these drugs are not about looks, but about health.
By treating obesity, we know we can reduce cardiovascular risk, and that may be only part of the cumulative benefits," he added.
The approval is based on a study of 17,000 patients that showed people taking Vigobi, the better-known sister drug to Ozampic, had a 20% lower risk for a cardiac event compared to those taking a placebo.
More in Walla!
Amy Schumer stopped taking Ozampic.
this is the reason
To the full article
Helping people at risk
"Vigobi is now the first weight loss drug also approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and obesity or overweight," the agency said in a press release.
"This patient population has a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that has been proven to lower this cardiovascular risk is a major advance for public health."
Novo Nordisk's trial was done in people with cardiovascular disease, meaning they had a heart attack or stroke or symptoms of peripheral artery disease - blocked arteries in the arms or legs.
More studies need to be done to show if there are cardiac benefits for people who have not had a cardiac event.
More on the same topic:
obesity
diabetes mellitus
Ozmpic
Heart Attack
Embed
heart diseases